Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: A retrospective series of 49 patients

Leukemia

Volumn 31, Issue 1, 2017, Pages 123-129

  Vignon, M ^a   Javaugue, V ^b   Alexander, M P ^c   El Karoui, K ^d   Karras, A ^e   Roos Weil, D ^f   Royer, B ^g   Asli, B ^a   Knebelmann, B ^d   Touchard, G ^b   Jaccard, A ^h,i   Arnulf, B ^a   Bridoux, F ^b,i   Leung, N ^c   Fermand, J P ^a  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c MAYO CLINIC   (United States)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

^h LIMOGES UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY OF LIMOGES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; GLUCOSE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN M; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; PHOSPHATE; URIC ACID; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; AMINOACIDURIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; ESTIMATED GLOMERULAR FILTRATION RATE; EXCRETION FRACTION; FANCONI RENOTUBULAR SYNDROME; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; LIGHT CHAIN; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MYELODYSPLASTIC SYNDROME; PHOSPHATE EXCRETION; PLASMA CELL; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; URIC ACID URINE LEVEL; FANCONI SYNDROME; HEMATOLOGIC NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PARAPROTEINEMIAS; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FANCONI SYNDROME; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY DISEASES; MALE; MIDDLE AGED; PARAPROTEINEMIAS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84986608462     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.195     Document Type: Article

References (29)

1. Maldonado JE, Velosa JA, Kyle RA, Wagoner RD, Holley KE, Salassa RM. Fanconi syndrome in adults. A manifestation of a latent form of myeloma. Am J Med 1975; 58: 354-364
2. Messiaen T, Deret S, Mougenot B, Bridoux F, Dequiedt P, Dion JJ et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine (Baltimore) 2000; 79: 135-154
3. Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand J-P et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012; 120: 4292-4295
4. Fermand J-P, Bridoux F, Kyle RA, Kastritis E, Weiss BM, Cook MA et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 2013; 122: 3583-3590
5. Ma CX, Lacy MQ, Rompala JF, Dispenzieri A, Rajkumar SV, Greipp PR et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 2004; 104: 40-42
6. Stokes MB, Valeri AM, Herlitz L, Khan AM, Siegel DS, Markowitz GS et al. Light chain proximal tubulopathy: clinical and pathologic characteristics in the modern treatment era. J Am Soc Nephrol JASN 2016; 27: 1555-1565
7. Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand J-P et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 2015; 87: 698-711
8. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541-4549
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
10. El Hamel C, Thierry A, Trouillas P, Bridoux F, Carrion C, Quellard N et al. Crystalstoring histiocytosis with renal Fanconi syndrome: pathological and molecular characteristics compared with classical myeloma-associated Fanconi syndrome. Nephrol Dial Transplant 2010; 25: 2982-2990
11. Bridoux F, Sirac C, Hugue V, Decourt C, Thierry A, Quellard N et al. Fanconi's syndrome induced by a monoclonal V-3 light chain in Waldenström's macroglobulinemia. Am J Kidney Dis 2005; 45: 749-757
12. Narvaez J, Domingo-Domenech E, Narvaez JA, Nolla JM, Valverde J. Acquired hypophosphatemic osteomalacia associated with multiple myeloma. Jt Bone Spine Rev Rheum 2005; 72: 424-426
13. Bate KL, Clouston D, Packham D, Ratnaike S, Ebeling PR. Lambda light chain induced nephropathy: a rare cause of the Fanconi syndrome and severe osteomalacia. Am J Kidney Dis 1998; 32: E3
14. Sirac C, Bridoux F, Essig M, Devuyst O, Touchard G, Cogné M. Toward understanding renal Fanconi syndrome: step by step advances through experimental models. Contrib Nephrol 2011; 169: 247-261
15. Sirac C, Bridoux F, Carrion C, Devuyst O, Fernandez B, Goujon J-M et al. Role of the monoclonal kappa chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome. Blood 2006; 108: 536-543
16. Leboulleux M, Lelongt B, Mougenot B, Touchard G, Makdassi R, Rocca et al. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int 1995; 48: 72-79
17. Larsen CP, Bell JM, Harris AA, Messias NC, Wang YH, Walker PD. The morphologic spectrum and clinical significance of light chain proximal tubulopathy with and without crystal formation. Mod Pathol 2011; 24: 1462-1469
18. Gu X, Barrios R, Cartwright J, Font RL, Truong L, Herrera GA. Light chain crystal deposition as a manifestation of plasma cell dyscrasias: the role of immunoelectron microscopy. Hum Pathol 2003; 34: 270-277
19. Herrera GA. Proximal tubulopathies associated with monoclonal light chains: the spectrum of clinicopathologic manifestations and molecular pathogenesis. Arch Pathol Lab Med 2014; 138: 1365-1380
20. Nasr SH, Galgano SJ, Markowitz GS, Stokes MB, D'Agati VD. Immunofluorescence on pronase-digested paraffin sections: a valuable salvage technique for renal biopsies. Kidney Int 2006; 70: 2148-2151
21. Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD atlas of renal pathology: light chain proximal tubulopathy. Am J Kidney Dis 2016; 67: e9-e10
22. Elliott MR, Cortese C, Moreno-Aspitia A, Dwyer JP. Plasma cell dyscrasia causing light chain tubulopathy without Fanconi syndrome. Am J Kidney Dis 2010; 55: 1136-1141
23. Said SM, Assaad AM, Cerda J, Nasr SH. Light chain tubulopathy without Fanconi syndrome. Nephrol Dial Transplant 2006; 21: 3589-3590
24. Figueres M-L, Beaume J, Vuiblet V, Rabant M, Bassilios N, Herody M et al. Crystalline light chain proximal tubulopathy with chronic renal failure and silicone gel breast implants: 1 case report. Hum Pathol 2015; 46: 165-168
25. Leung N, Nasr SH. Myeloma-related kidney disease. Adv Chronic Kidney Dis 2014; 21: 36-47
26. Stokes MB, Aronoff B, Siegel D, D'Agati VD. Dysproteinemia-related nephropathy associated with crystal-storing histiocytosis. Kidney Int 2006; 70: 597-602
27. Chauvet S, Bridoux F, Ecotière L, Javaugue V, Sirac C, Arnulf B et al. Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients. Am J Kidney Dis 2015; 66: 756-767
28. Duquesne A, Werbrouck A, Fabiani B, Denoyer A, Cervera P, Verpont MC et al. Complete remission of monoclonal gammopathy with ocular and periorbital crystal storing histiocytosis and Fanconi syndrome. Hum Pathol 2013; 44: 927-933
29. Nishida Y, Iwama K, Yamakura M, Takeuchi M, Matsue K. Renal Fanconi syndrome as a cause of chronic kidney disease in patients with monoclonal gammopathy of undetermined significance: partially reversed renal function by high-dose dexamethasone with bortezomib. Leuk Lymphoma 2012; 53: 1804-1806.